Insider Buying: ImmunoVaccine Inc. (IMV) Insider Acquires 20,800 Shares of Stock

ImmunoVaccine Inc. (TSE:IMV) insider Pierre Labbé purchased 20,800 shares of the stock in a transaction on Monday, February 12th. The shares were purchased at an average price of C$1.89 per share, for a total transaction of C$39,312.00.

ImmunoVaccine Inc. (IMV) remained flat at $C$1.89 during midday trading on Tuesday. 55,867 shares of the stock were exchanged, compared to its average volume of 143,038. ImmunoVaccine Inc. has a 1 year low of C$1.00 and a 1 year high of C$2.55. The firm has a market cap of $246.44, a PE ratio of -21.22 and a beta of 0.47.

TRADEMARK VIOLATION WARNING: “Insider Buying: ImmunoVaccine Inc. (IMV) Insider Acquires 20,800 Shares of Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/13/insider-buying-immunovaccine-inc-imv-insider-acquires-20800-shares-of-stock.html.

About ImmunoVaccine

Immunovaccine Inc, a clinical stage biopharmaceutical company, develops cancer immunotherapies and infectious disease vaccines based on its DepoVax platform. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.

Receive News & Ratings for ImmunoVaccine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoVaccine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply